Technology
Health
Pharmaceutical
Genprex
$1.609876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.02 (1.43%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Genprex and other stocks, options, ETFs, and crypto commission-free!
About
Genprex, Inc. Common Stock, also called Genprex, is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. Read More It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Employees
7
Headquarters
Austin, Texas
Founded
2009
Market Cap
24.42M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
53.23K
High Today
$1.58
Low Today
$1.58
Open Price
$1.58
Volume
516.00
52 Week High
$12.24
52 Week Low
$0.95
Collections
Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
Medical
2018 IPO
US
News
Yahoo FinanceMay 9
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (GNPX) announces the availability of a NetworkNewsAudio publication titled, “New Gene Therapies Hold Out Promise for Patients.” To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/D55vd To read the full editorial, visit: http://nnw.fm/nhjN4 Gene therapies, the promising treatments pursued by companies such as Genprex Inc. (GNPX) , are based on turning [the] problem [of cell mutation] on its head. These therapies ...
PR NewswireMay 7
New Gene Therapies Hold Out Promise for Patients
NEW YORK, May 7, 2019 /PRNewswire/ -- Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body's damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia. Genprex Inc. (NASDAQ:GNPX) (GNPX Profile) is developing gene therapies for the treatment of cancer, including its initialdrug ca...
Price Paid on Robinhood
50% Lower
Right Now
52 Week Low
$0.95
Average Price Paid
$3.21
52 Week High
$12.24
Earnings
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Available May 15